Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2023
Event: Announcement of a Research and Development (R&D) Day held on October 18, 2023.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a notification of a corporate event and does not report financial performance for any period.
Material Changes
No material financial changes or operational updates regarding historical performance are reported in this filing. The primary activity is the presentation of the company's pipeline, specifically focusing on:
- SPN-820/821
- SPN-817
- New clinical candidates from the discovery program
Guidance, Outlook, and Risks
Management Commentary: The company hosted an R&D Day to discuss its pipeline. A presentation was furnished as Exhibit 99.1 and is available via webcast archive on the company website for 60 days.
Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the Risk Factors section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Legal Status of Information: Information in Item 7.01 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the content of the R&D Day presentation (Exhibit 99.1) on the company's Investor Relations website.
- Review the Form 10-K for the fiscal year ended December 31, 2022, for detailed risk factors referenced in this filing.
- Confirm the availability of the archived webcast within the 60-day window following the event.